Table 1.

Monoclonal antibodies used in this study

	MAb	Region	Species	EC50 value (ng/ml) a	block ACE2 binding	Binds RBM	Structural contacts	Functionally important residues b	Other mapping data	Reference
CLASS 1	COV2-2196	RBD - RBM	human	15	yes	yes		F486A, N487A (LOB)		(Dong et al., 2021; Zost et al., 2020a; Zost et al., 2020b)
	COV2-2130	RBD - RBM	human	107	yes	yes		K444A, G447R (LOB); and R346I, K444R, K444E (NE)		(Dong et al., 2021; Zost et al., 2020a; Zost et al., 2020b)
	COV2-2072	RBD - RBM	human	26	yes	yes			COV2-2196 competitive	(Zost et al., 2020a; Zost et al., 2020b)
	COV2-2050	RBD - RBM	human	80	yes	yes		E484K (LOB and NE)	COV2-2196 and COV2-2130 competitive	(Greaney et al., 2021; Zost et al., 2020a; Zost et al., 2020b)
	COV2-3025	RBD - RBM	human	37	yes	yes			COV2-2196 competitive	(Zost et al., 2020a; Zost et al., 2020b)
	COV2-2381	RBD - RBM	human	42	yes	yes			COV2-2196 competitive	(Zost et al., 2020a; Zost et al., 2020b)
	1B07	RBD - RBM	mouse-human chimera	279	yes	yes		E484A/D/G/K, F486Y (NE)		(Alsoussi et al., 2020; Liu et al., 2020)
	S2E12	RBD - RBM	human	4.2	yes	yes	455 to 458, 473 to 493	G476S, F486A (LOB)		(Tortorici et al., 2020), Starr, Corti et al. unpublished
	COVOX-384	RBD - RBM	human	2	yes	yes	L455, F456, G482-F486			Dejnirattisai and Screaton, unpublished
	COVOX-40	RBD - RBM	human	24	yes	yes	K417, Q409, Y505			Dejnirattisai and Screaton, unpublished
	S2H58	RBD-RBM	human	5	yes	yes		E484K, F490L, S494P (LOB)		Starr, Corti et al. unpublished
	S2X259	RBD	human	55	yes	no		G504D (LOB)		McCallum, Corti et al, unpublished
CLASS 2	S309	RBD-BASE	human	79	no	no	T333-L335,P337,G339-V341,N343R346,N354,K356-C361,N440L441,K444,R509			(Pinto et al., 2020)
	SARS2-31	RBD-BASE	mouse	246	yes	no		K378E/Q, R408K, G504D (NE)	CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2-10	RBD-BASE	mouse	694	yes	no			CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2-54	RBD-BASE	mouse	32	yes	no			CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2-44	RBD-BASE	mouse	258	yes	no			CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2-3	RBD-BASE	mouse	670	no	no			CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2-65	RBD-BASE	mouse	145	no	no			CR3022 competitive	VanBlargan and Diamond, unpublished
CLASS 3	COV2-2676	NTD	human	501	no	no		Y144A, N164A (LOB) and F140S (NE)		(Suryadevara et al., 2021; Zost et al., 2020a; Zost et al., 2020b)
	COV2-2489	NTD	human	199	no	no		G142A, Y144A, F157A, N164A (LOB); and G142D, R158S (NE)		(Suryadevara et al., 2021; Zost et al., 2020a; Zost et al., 2020b)

^aNeutralization potency determined by FRNT assay with WA1/2020 isolate.

^bLOB, loss-of-binding to spike protein, and NE, neutralization escape mutants.